Article Figures & Data
Figures
- Figure 1.
Visual Model of Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) and Programmed Death Ligand 1 (PD-L1) Action. TCR, T-cell receptor; MHC, major histocompatibility complex; CD28, cluster of differentiation 28; CD80, cluster of differentiation 80.
- Figure 2.
Flowchart of the Chimeric Antigen Receptor (CAR) T-Cell Process.
Tables
Drug Immune-Mediated Side Effect Colitis Pneumonitis Hepatitis Adrenal Insufficiency Thyroid Dysfunction Hypophysitis Diabetes Mellitus 1 Renal Dysfunction Pembrolizumab 1.7% 3.4% 0.7% 0.0% 12.5% 0.6% 0.2% 0.3% Atezolizumab 19.7% 2.6% 2.3% 0.4% 4.9% 0.2% 0.2% 0.0% Nivolumab 2.9% 3.1% 1.8% 1.0% 11.7% 0.6% 0.9% 1.2% Avelumab 1.5% 1.2% 0.9% 0.5% 6.0% 0.0% 0.1% 0.1% Nivolumab Side Effect Mean Time to Onset, Months Hyperthyroidism 1.5 Rash 2.8 Hypothyroidism 2.9 Hepatitis 3.3 Adrenal Insufficiency 4.3 Diabetes Mellitus Type 1 4.4 Nephritis/Renal Dysfunction 4.6 Hypophysitis 4.9 Colitis 5.3 Encephalitis 7.2
